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Abstract. Given that early-onset type 2 diabetes mellitus 
(T2DM), metabolic syndrome (MetS), and hyperuricemia 
have been shown to have strong genetic components, the statis-
tical power of a genetic association study may be increased 
by focusing on early-onset subjects with these conditions. 
Although genome-wide association studies have identified 
various genes and loci significantly associated with T2DM, 
MetS, and hyperuricemia, genetic variants that contribute to 
predisposition to these conditions in Japanese subjects remain 
to be identified definitively. We performed exome-wide 
association studies (EWASs) for early-onset T2DM, MetS, 
or hyperuricemia to identify genetic variants that confer 
susceptibility to these conditions. A total of 8,102 individuals 
aged ≤65 years were enrolled in the present study. The EWAS 
for T2DM was performed with 7,407 subjects (1,696 cases, 
5,711 controls), that for MetS with 4,215 subjects (2,296 cases, 
1,919 controls), and that for hyperuricemia with 7,919 subjects 
(1,365 cases, 6,554 controls). Single nucleotide polymorphisms 
(SNPs) were genotyped with Illumina Human Exome-12 DNA 
Analysis BeadChip or Infinium Exome‑24 BeadChip arrays. 
The relationship of allele frequencies for 31,210, 31,521, or 
31,142 SNPs that passed quality control for T2DM, MetS, or 
hyperuricemia, respectively, was examined with Fisher's exact 
test. To compensate for multiple comparisons of genotypes 
with T2DM, MetS, or hyperuricemia, we applied Bonferroni's 
correction for statistical significance of association. The EWAS 
of allele frequencies revealed that four, six, or nine SNPs were 
significantly associated with T2DM (P<1.60x10-6), MetS 
(P<1.59x10-6), or hyperuricemia (P<1.61x10-6), respectively. 
Multivariable logistic regression analysis with adjustment 
for age and sex revealed that three, six, or nine SNPs were 
significantly related to T2DM (P<0.0031), MetS (P<0.0021), 
or hyperuricemia (P<0.0014). After examination of the 
association of identified SNPs to T2DM‑, MetS‑, or hyperuri-
cemia-related traits, linkage disequilibrium of the SNPs, and 
results of previous genome-wide association studies, newly 
identified ZNF860 and OR4F6 were the susceptibility loci 
for T2DM, OR52E4 and OR4F6 for MetS, and HERPUD2 
for hyperuricemia. Given that OR4F6 was significantly asso-
ciated with both T2DM and MetS, we newly identified four 
genes (ZNF860, OR4F6, OR52E4, HERPUD2) that confer 
susceptibility to early-onset T2DM, MetS, or hyperuricemia. 
Determination of genotypes for the SNPs in these genes may 
prove informative for assessment of the genetic risk for T2DM, 
MetS, or hyperuricemia.
Introduction
Diabetes mellitus (DM) has reached epidemic proportions 
and affects more than 382 million individuals worldwide (1): 
The number of patients with DM is expected to increase 
beyond 592 million individuals by 2035 (1). Approximately 
90 to 95% of individuals with DM have type 2 DM (T2DM), 
the characteristics of which can range from predominant 
insulin deficiency with relatively minor insulin resistance to 
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predominant insulin resistance with relatively minor insulin 
deficiency (2). T2DM is a major cause of nephropathy, reti-
nopathy, and neuropathy as well as cardiovascular disease 
and stroke (3,4). Although obesity resulting from a seden-
tary lifestyle and overeating is an important risk factor for 
T2DM, genetic components are involved in the pathogenesis 
of this condition, given that a positive family history confers 
a 2.4‑fold increased risk for T2DM (5). The heritability of 
T2DM has been estimated to be 50 to 60% (6).
Genome-wide association studies (GWASs) and meta-anal-
yses have identified >120 susceptibility loci for T2DM (7) 
in individuals of European (8-13) or African (14) ancestry, 
in East Asians (15), or in multiple ethnic groups (16,17). 
Among Japanese, GWASs have identified KCNQ1, UBE2E2, 
and C2CD4A‑B (18-20) as susceptibility genes for T2DM, 
and a recent meta-analysis identified an additional seven 
susceptibility loci for this condition (21). Genetic variants that 
contribute to predisposition to T2DM in Japanese subjects, 
however, remain to be identified definitively.
Metabolic syndrome (MetS) is a cluster of metabolic traits 
including abdominal obesity, an increased serum triglycerides, 
a decreased serum high-density lipoprotein (HDL) cholesterol, 
high blood pressure (BP), and an increased fasting plasma 
glucose (FPG) level (22). MetS is a risk factor for athero-
sclerotic cardiovascular disease, DM (23), and cancer (24). The 
etiology of MetS is highly complex, with both genetic and envi-
ronmental factors being thought to play important roles. The 
heritability of MetS has been estimated to be approximately 
50% (25) and traits of this syndrome to be 28 to 48% (26).
GWASs have suggested various loci or genes involved 
in predisposition to MetS or to traits of this syndrome in 
individuals of European (27,28) or African (29) ancestry or 
in Asian Indians (30) or Chinese individuals  (31). However, 
genetic variants that contribute to predisposition to MetS in 
Japanese individuals remain to be identified definitively.
Circulating uric acid levels are regulated by multiple renal 
transporters by mediating the excretion or reabsorption of 
uric acid in the proximal kidney tubules (32). Hyperuricemia 
is an important risk factor for gout, a common inflammatory 
arthritis (33), as well as for cardiovascular disease (34) and 
cancer (35). The heritability of the serum concentration of uric 
acid has been estimated to be 40% (36), suggesting that genetic 
variants contribute to regulation of the serum uric acid level by 
influencing uric acid synthesis, excretion, or reabsorption (36,37).
GWASs have identified single nucleotide polymorphisms 
(SNPs) significantly associated with the serum uric acid 
concentration or the prevalence of gout (38‑45). A large‑scale 
GWAS in European ancestry populations identified 28 loci 
that influence the serum concentration of uric acid (46). 
Although several SNPs have been shown to be associated 
with gout in Japanese (47,48), genetic variants that contribute 
to predisposition to hyperuricemia in Japanese remain to be 
identified definitively.
In a family study of T2DM, a heritability of T2DM was 
higher in early-onset than late-onset individuals (6). These 
observations indicate that early-onset T2DM has a strong 
genetic component (6,49). Similar to T2DM, early-onset forms 
of MetS (50,51), hyperuricemia, and gout (52,53) have been 
shown to have strong genetic components. Given that genetic 
contribution may be greater in early-onset forms of T2DM, 
MetS, and hyperuricemia than in late-onset forms, statistical 
power of the genetic association study may be increased by 
focusing on early-onset subjects with these conditions.
In the present study, we performed exome-wide association 
studies (EWASs) with the use of human exome array-based 
genotyping methods to identify genetic variants that confer 
susceptibility to early-onset T2DM, MetS, or hyperuricemia in 
Japanese patients. To increase the statistical power of EWASs, 
early-onset subjects were examined.
Materials and methods
Study subjects. In previous studies, the median age of subjects 
with T2DM (54), MetS (55), or hyperuricemia (56) was 68, 64, or 
62 years, respectively. We thus defined subjects aged ≤65 years 
as early-onset cases in the present study. A total of 8,102 indi-
viduals aged ≤65 years were examined. The subjects were 
recruited from individuals either who visited outpatient clinics 
of or were admitted to participating hospitals in Japan (Gifu 
Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General 
Medical Center, Gifu; Japanese Red Cross Nagoya First 
Hospital, Nagoya; Northern Mie Medical Center Inabe General 
Hospital, Inabe; Hirosaki University Hospital and Hirosaki 
Stroke and Rehabilitation Center, Hirosaki) because of various 
symptoms or for an annual health checkup between October 
2002 and March 2014; or who were community‑dwelling indi-
viduals recruited to a population-based cohort study in Inabe 
between March 2010 and september 2014 (57).
T2DM was defined according to the criteria of the World 
Health Organization as described previously (2,58,59). 
Subjects with T2DM had an FPG level of ≥6.93 mmol/l 
(126 mg/dl) or a blood hemoglobin A1c content of ≥6.5% or 
were taking antidiabetes medication. Individuals with T1DM, 
maturity-onset diabetes of the young, DM associated with 
mitochondrial diseases or single-gene disorders, pancreatic 
diseases, or other metabolic or endocrinologic diseases were 
excluded from the study. Those taking medications that may 
cause secondary DM were also excluded. The control subjects 
had an FPG level of <6.05 mmol/l (110 mg/dl), a blood 
hemoglobin A1c content of <6.2%, and no history of DM or 
of having taken antidiabetes medication. We thus examined 
1,696 subjects with T2DM and 5,711 controls.
Diagnosis of MetS was based on a modified version of the 
definition proposed by the International Diabetes Federation 
Task Force on Epidemiology and Prevention; National Heart, 
Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; and 
International Association for the Study of Obesity (22). We 
used cut‑off values for waist circumference of ≥90 cm in 
men or ≥80 cm in women on the basis of a recommendation 
of the International Diabetes Association (22). A total of 
2,296 subjects with MetS thus had three or more of the following 
five components: i) A waist circumference of ≥90 cm for men 
or ≥80 cm for women; ii) a serum triglyceride concentration 
of ≥1.65 mmol/l (150 mg/dl) or drug treatment for elevated 
triglycerides; iii) a serum HDL‑cholesterol concentration of 
<1.04 mmol/l (40 mg/dl) for men or <1.30 mmol/l (50 mg/dl) 
for women; iv) a systolic BP of ≥130 mmHg, diastolic BP of 
≥85 mmHg, or drug treatment for hypertension; and v) an 
FPG level of ≥5.50 mmol/l (100 mg/dl) or drug treatment 
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for elevated glucose. History of obesity, dyslipidemia, hyper-
tension, or DM was evaluated with a detailed questionnaire. 
The control subjects comprised 1,919 individuals who had 
none of the five traits of MetS.
Hyperuricemia was defined as a serum uric acid concentra-
tion of >416 µmol/l (7 mg/dl) or taking of uric acid‑lowering 
medication. Individuals taking drugs that potentially caused 
secondary hyperuricemia were excluded. The control indi-
viduals for the study of hyperuricemia had a serum uric acid 
concentration of ≤416 µmol/l and had no history of hyper-
uricemia or gout or of taking uric acid-lowering medication. 
Thus, we examined 1,365 subjects with hyperuricemia and 
6,554 controls.
The 1,040 subjects with both T2DM and MetS as well as 
1,884 controls overlapped between the corresponding studies, 
as did the 375 subjects with both T2DM and hyperuricemia 
and 4,809 controls as well as the 628 subjects with both MetS 
and hyperuricemia and 1,771 controls.
EWASs. Venous blood (5‑7 ml) was collected into tubes 
containing 50 mmol/l ethylenediaminetetraacetic acid (diso-
dium salt), peripheral blood leukocytes were isolated, and 
genomic DNA was extracted from these cells either with 
the use of a kit (Genomix from Talent Srl, Trieste, Italy or 
SMITEST EX-R&D from Medical & Biological Laboratories, 
Co., Ltd., Nagoya, Japan).
The EWAS for T2DM, MetS, or hyperuricemia included 
7,407 individuals (1,696 subjects with T2DM, 5,711 controls), 
4,215 individuals (2,296 subjects with MetS, 1,919 controls), 
or 7,919 individuals (1,365 subjects with hyperuricemia, 
6,554 controls), respectively. The EWASs were performed with 
the use of a Human Exome-12 v1.2 DNA Analysis BeadChip 
or Infinium Exome‑24 v1.0 BeadChip (Illumina, San Diego, 
CA, USA). These exome arrays include putative functional 
exonic variants selected from ~12,000 individual exome and 
whole-genome sequences. The exonic content consisted of 
~244,000 SNPs from diverse populations, including European, 
African, Chinese, and Hispanic individuals (60). SNPs 
contained in only one exome array (~2.6% of all SNPs) were 
excluded from analysis. We performed quality control (61) 
as follows: i) Genotyping data with a call rate of <97% were 
discarded, with the mean call rate for the remaining data being 
99.9%. ii) Sex specification was checked for all the samples, 
and those for which sex phenotype in the clinical records was 
inconsistent with genetic sex were discarded. iii) Duplicated 
samples and cryptic relatedness were checked by calculation 
Table I. Characteristics of subjects with type 2 diabetes mellitus and control individuals.
Characteristic Control Type 2 diabetes mellitus P-value
No. of subjects 5,711 1,696 
Age (years)   50.4±10.2 56.3±7.2 <0.0001
Sex (men/women, %) 52.1/47.9 76.2/23.8 <0.0001
Smoking (%) 40.0 47.5   0.0105
Obesity (%) 28.1 45.2 <0.0001
Body mass index (kg/m2) 22.9±3.3 24.7±3.9 <0.0001
Hypertension (%) 32.0 71.0 <0.0001
Systolic BP (mmHg) 122±20 140±27 <0.0001
Diastolic BP (mmHg)   75±13   80±15 <0.0001
Fasting plasma glucose (mmol/l)   5.17±0.48   8.95±3.77 <0.0001
Blood hemoglobin A1c (%)   5.48±0.31   7.33±1.87 <0.0001
Dyslipidemia (%) 54.4 80.2 <0.0001
Serum triglycerides (mmol/l)   1.29±0.89   1.82±1.47 <0.0001
Serum HDL‑cholesterol (mmol/l)   1.62±0.46   1.32±0.43 <0.0001
Serum LDL‑cholesterol (mmol/l)   3.14±0.82   3.15±0.97   0.8052
Chronic kidney disease (%) 10.9 26.8 <0.0001
Serum creatinine (µmol/l)   70.4±63.1     93.1±122.6 <0.0001
eGFR (ml min-1 1.73 m-2)   78.4±18.9   73.2±24.6 <0.0001
Hyperuricemia (%) 14.5 22.9 <0.0001
Serum uric acid (µmol/l) 321±90   340±102 <0.0001
Quantitative data are means ± standard deviations and were compared between subjects with type 2 diabetes mellitus and controls with the 
unpaired Student's t-test. Categorical data were compared between two groups with Pearson's Chi-square test. Based on Bonferroni's correction, 
a P‑value of <0.0026 (0.05/19) was considered statistically significant. Definitions of diseases: Obesity, body mass index of ≥25 kg/m2; hyper-
tension, systolic BP of ≥140 mmHg, diastolic BP of ≥90 mmHg, or taking of anti‑hypertensive medication; dyslipidemia, serum triglyceride 
concentration of ≥1.65 mmol/l, serum HDL‑cholesterol concentration of <1.04 mmol/l, serum LDL‑cholesterol concentration of ≥3.64 mmol/l, 
or taking of anti‑dyslipidemic medication; chronic kidney disease, eGFR of <60 ml min-1 1.73 m-2; hyperuricemia, serum uric acid concentration 
of >416 µmol/l or taking of uric acid‑lowering medication. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; 
eGFR, estimated glomerular filtration rate.
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of identity by descent, with all the pairs of samples showing a 
value of >0.1875 being inspected and one sample from each 
pair excluded. iv) Heterozygosity of SNPs was calculated for 
all the samples, and those with extremely low or high heterozy-
gosity (>3 standard deviations from the mean) were discarded. 
v) SNPs in sex chromosomes or mitochondrial DNA were 
excluded from the analysis, as were non-polymorphic SNPs 
or SNPs with a minor allele frequency of <1.0%. vi) SNPs 
whose genotype distributions deviated significantly (P<0.01) 
from the Hardy-Weinberg equilibrium in control individuals 
were discarded. vii) Genotype data were examined for popula-
tion stratification by principal components analysis (62), and 
population outliers were excluded. Totals of 31,210, 31,521, 
or 31,142 SNPs passed quality control for the T2DM, MetS, 
and hyperuricemia studies, respectively, and were subjected 
to analysis.
Statistical analysis. For analysis of characteristics of the 
study subjects, quantitative or categorical data were compared 
between individuals with T2DM, MetS, or hyperuricemia and 
corresponding controls with the unpaired Student's t-test or 
Pearson's Chi-square test, respectively. Allele frequencies were 
estimated by the gene counting method, and Fisher's exact test 
was used to identify departure from Hardy-Weinberg equilib-
rium. The relationship of allele frequencies of SNPs to T2DM, 
MetS, or hyperuricemia in the EWAS was examined using the 
Fisher's exact test. To compensate for multiple comparisons 
of allele frequencies with T2DM, MetS, or hyperuricemia, 
we applied Bonferroni's correction for statistical significance 
of association. The significance level was set at P<1.60x10-6 
(0.05/31210), P<1.59x10 -6 (0.05/31521), or P<1.61x10 -6 
(0.05/31142) for the EWAS of T2DM, MetS, or hyperuricemia, 
respectively. The inflation factor (λ) was 1.04 for T2DM, 1.05 
for MetS, or 1.09 for hyperuricemia. Multivariable logistic 
regression analysis was performed with T2DM, MetS, hyper-
uricemia as a dependent variable and independent variables 
including age, sex (0, woman; 1, man), and genotype of each 
SNP. Genotypes of each SNP were assessed according to 
dominant [0, AA; 1, AB + BB (A, major allele; B, minor allele)], 
recessive (0, AA + AB; 1, BB), and additive genetic models, and 
the P‑value, OR, and 95% confidence interval were calculated. 
Additive models comprised additive 1 (0, AA; 1, AB; 0, BB) 
and additive 2 (0, AA; 0, AB; 1, BB) scenarios, which were 
analyzed simultaneously with a single statistical model. The 
relation of genotypes of identified SNPs to T2DM‑, MetS‑, 
or hyperuricemia-related traits was examined by one-way 
analysis of variance (ANOVA). Bonferroni's correction was 
also applied to other statistical analysis as indicated. Statistical 
tests were performed with JMP Genomics version 9.0 software 
(SAS Institute, Cary, NC, USA).
Results
Characteristics of subjects. The characteristics of the 
7,407 subjects enrolled in the T2DM study are shown 
in Table I. Age, the frequency of men, and the prevalence of 
obesity, hypertension, dyslipidemia, chronic kidney disease 
(CKD), and hyperuricemia as well as body mass index (BMI), 
Table II. Characteristics of subjects with metabolic syndrome and control individuals.
Characteristic Control Metabolic syndrome P-value
No. of subjects 1,919 2,296 
Age (years)   47.0±10.7 55.0±8.0 <0.0001
Sex (men/women, %) 42.3/57.7 67.9/32.1 <0.0001
Smoking (%) 35.2 46.1 <0.0001
Waist circumference (cm) 74.0±6.0 88.3±9.0 <0.0001
Body mass index (kg/m2) 20.8±2.2 26.0±3.7 <0.0001
Systolic BP (mmHg) 109±11 140±25 <0.0001
Diastolic BP (mmHg) 67±9   83±14 <0.0001
Fasting plasma glucose (mmol/l)   4.97±0.36   7.25±3.07 <0.0001
Blood hemoglobin A1c (%)   5.39±0.29   6.58±1.60 <0.0001
Serum triglycerides (mmol/l)   0.82±0.30   2.17±1.46 <0.0001
Serum HDL‑cholesterol (mmol/l)   1.86±0.42   1.24±0.37 <0.0001
Serum LDL‑cholesterol (mmol/l)   2.95±0.74   3.28±0.96 <0.0001
Chronic kidney disease (%) 15.9 56.6 <0.0001
Serum creatinine (µmol/l)   63.0±18.2   84.4±97.5 <0.0001
eGFR (ml min-1 1.73 m-2)   81.6±17.0   73.3±23.5 <0.0001
Hyperuricemia (%) 5.2 28.0 <0.0001
Serum uric acid (µmol/l) 286±76 356±97 <0.0001
Quantitative data are means ± standard deviations and were compared between subjects with metabolic syndrome and controls with the 
unpaired Student's t-test. Categorical data were compared between two groups with Pearson's Chi-square test. Base on Bonferroni's correction, 
a P‑value of <0.0029 (0.05/17) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; eGFR, estimated glomerular filtration rate. Definitions of chronic kidney disease and hyperuricemia are described in Table I.
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systolic and diastolic BP, and serum concentrations of triglyc-
erides, creatinine, and uric acid were greater, whereas serum 
concentration of HDL-cholesterol and estimated glomerular 
filtration rate (eGFR) were lower, in subjects with T2DM than 
in controls.
Characteristics of the 4,215 subjects enrolled in the MetS 
study are shown in Table II. Age, the frequency of men, and 
the prevalence of smoking, CKD, and hyperuricemia as well as 
BMI, blood hemoglobin A1c content, and serum concentrations 
of low-density lipoprotein (LDL) cholesterol, creatinine, and 
uric acid were greater, whereas eGFR were lower, in subjects 
with MetS than in controls.
Characteristics of the 7,919 subjects enrolled in the hyper-
uricemia study are shown in Table III. Age, the frequency 
of men, and the prevalence of smoking, obesity, hyperten-
sion, DM, dyslipidemia, and CKD as well as BMI, systolic 
and diastolic BP, FPG level, and serum concentrations of 
triglycerides and creatinine were greater, whereas the serum 
concentration of HDL-cholesterol and eGFR were lower, in 
subjects with hyperuricemia than in controls.
EWAS for T2DM, MetS, or hyperuricemia. We examined 
the relationship of allele frequencies of 31,210 SNPs that 
passed quality control to T2DM with the use of Fisher's exact 
test. After Bonferroni's correction, four SNPs were signifi-
cantly (P<1.60x10-6) associated with T2DM (Table IV). The 
relationship of allele frequencies of 31,521 SNPs to MetS was 
examined with Fisher's exact test. After Bonferroni's correc-
tion, six SNPs were significantly (P<1.59x10-6) associated 
with MetS (Table V). The relationship of allele frequencies 
of 31,142 SNPs to hyperuricemia was also examined with 
Fisher's exact test. After Bonferroni's correction, nine SNPs 
were significantly (P<1.61x10-6) associated with hyperuri-
cemia (Table VI).
Multivariable logistic regression analysis of the relationship 
of SNPs to T2DM, MetS, or hyperuricemia. The relationship of 
the four identified SNPs in the EWAS of T2DM to this condi-
tion was further examined by multivariable logistic regression 
analysis with adjustment for age and sex (Table VII). Three 
SNPs (rs141569282 of OR4F6, rs140232911 of ZNF860, 
rs150552771 of LPGAT1) were significantly [P<0.0031 
(0.05/16) in at least one genetic model] related to T2DM. The 
relationship of the six SNPs identified in the EWAS for MetS to 
this condition was examined by multivariable logistic regres-
sion analysis with adjustment for age and sex (Table VIII). All 
the SNPs were significantly [P<0.0021 (0.05/24)] related to 
MetS. The relationship of the 9 SNPs identified by the EWAS 
of hyperuricemia to this condition was also examined by 
multivariable logistic regression analysis with adjustment for 
age and sex (Table IX). All SNPs were significantly [P<0.0014 
(0.05/36)] related to hyperuricemia.
Table III. Characteristics of subjects with hyperuricemia and control individuals.
Characteristic Control Hyperuricemia P-value
No. of subjects 6,554 1,365 
Age (years) 51.5±9.9 52.9±9.1 <0.0001
Sex (men/women, %) 52.6 /47.4 90.2/9.8 <0.0001
Smoking (%) 38.3 61.6 <0.0001
Obesity (%) 30.0 47.4 <0.0001
Body mass index (kg/m2) 23.2±3.5 24.8±3.8 <0.0001
Hypertension (%) 38.2 62.0 <0.0001
Systolic BP (mmHg) 126±23 134±24 <0.0001
Diastolic BP (mmHg)   75±14   82±15 <0.0001
Diabetes mellitus (%) 20.8 31.6 <0.0001
Fasting plasma glucose (mmol/l)   6.04±2.38   6.25±2.27   0.0022
Blood hemoglobin A1c (%)   5.96±1.26   6.10±1.28   0.0042
Dyslipidemia (%) 57.9 79.0 <0.0001
Serum triglycerides (mmol/l)   1.34±0.99   1.90±1.38 <0.0001
Serum HDL‑cholesterol (mmol/l)   1.57±0.47   1.37±0.42 <0.0001
Serum LDL‑cholesterol (mmol/l)   3.15±0.85   3.20±0.93   0.0506
Chronic kidney disease (%) 11.0 33.0 <0.0001
Serum creatinine (µmol/l)   68.7±52.3   109.4±150.3 <0.0001
eGFR (ml min-1 1.73 m-2)   79.2±18.3   67.4±25.8 <0.0001
Serum uric acid (µmol/l) 296±67 455±78 <0.0001
Quantitative data are means ± standard deviations and were compared between subjects with hyperuricemia and controls with the unpaired 
Student's t-test. Categorical data were compared between two groups with Pearson's Chi-square test. Base on Bonferroni's correction, a P-value 
of <0.0026 (0.05/19) was considered statistically significant. Definition of diabetes mellitus, fasting plasma glucose level of ≥6.93 mmol/l, 
blood hemoglobin A1c content of ≥6.5%, or taking of antidiabetes medication. Definitions of other diseases are described in Table I. BP, blood 
pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.
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Relationship of SNPs associated with T2DM to FPG level or 
blood hemoglobin A1c content. We examined the relationship 
of genotypes for the 3 SNPs associated with T2DM to FPG 
level or blood hemoglobin A1c content by one-way ANOVA 
(Table X). A SNP rs141569282 of OR4F6 was significantly 
[P<0.0083 (0.05/6)] associated with FPG level and blood 
hemoglobin A1c content, and rs140232911 of ZNF860 with 
blood hemoglobin A1c content.
Relationship of SNPs associated with MetS to each trait 
of MetS. We examined the relationship of genotypes for 
the six SNPs associated with MetS to waist circumference, 
serum concentrations of triglycerides and HDL-cholesterol, 
systolic and diastolic BP, and FPG level by one-way ANOVA 
(Table XI). Three SNPs (rs1053266 of CCDC6, rs141569282 
of OR4F6, rs200716952 of HLA‑DQB2) were significantly 
(P<0.0014) related to all the traits; rs2075291 of APOA5 to 
waist circumference and serum concentrations of triglyc-
erides and HDL‑cholesterol; rs11823828 of OR52E4 to 
serum concentrations of triglycerides and HDL-cholesterol, 
systolic BP, and FPG level; and rs17482753 at chromo-
some 8p21.3 to serum concentrations of triglycerides and 
HDL-cholesterol.
Relationship of SNPs associated with hyperuricemia to 
serum concentrations of uric acid. We examined the relation-
ship of the 9 SNPs associated with hyperuricemia to serum 
concentrations of uric acid by one-way ANOVA (Table XII). 
Seven SNPs (rs121907892 of SLC22A12, rs3782886 of BRAP, 
rs11066015 of ACAD10, rs11066280 of HECTD4, rs12229654 
at chromosome 12q24.1, rs3775948 of SLC2A9, rs2305335 of 
HERPUD2) were significantly (P<0.0056) associated with 
serum concentrations of uric acid.
Linkage disequilibrium (LD) analyses. We examined LD in 
SNPs associated with MetS or hyperuricemia. For the MetS 
study, rs11823828 of OR52E4 and rs2075291 of APOA5 were 
not in LD [square of the correlation coefficient (r2)<0.001]. For 
the hyperuricemia study, 6 SNPs were located at chromosomal 
12q24.11 to 12q24.13. LD plots of these SNPs are shown 
in Fig. 1. Strong LD was observed between rs10849915 and 
rs10774610 of CCDC63 (r2, 0.991) and among rs3782886 of 
BRAP, rs11066015 of ACAD10, and rs11066280 of HECTD4 
(r2, 0.876 to 0.941).
Relation of genes, chromosomal loci, and SNPs identified in 
the present study to phenotypes reported by previous GWASs. 
Table X. Relation of SNPs identified in the present study to fasting plasma glucose level and blood hemoglobin A1c content.
Gene SNP Pasting plasma glucose (mmol/l) P-value Blood hemoglobin A1c (%) P‑value
OR4F6 rs141569282 G/A GG GA <0.0001 GG GA <0.0001
   6.26±2.76 5.35±0.71  6.15±1.46 5.57±0.43 
ZNF860 rs140232911 C/T CC CT   0.6279 CC CT   0.0070
   6.06±2.46 6.25±1.97  5.52±0.73 6.00±1.32 
LPGAT1 rs150552771 T/C TT TC   0.6320 TT TC   0.3280
   6.05±2.45 6.63±3.88  5.35±0.53 5.99±1.31 
Data are means ± standard deviations and compared among genotypes by one‑way analysis of variance. Based on Bonferroni's correction, 
P‑values of <0.0083 (0.05/6) were considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism.
Figure 1. LD map of six SNPs at 12q24.11 to 12q24.13 associated with hyperuricemia. LD was calculated as the square of the correlation coefficient (r2) and 
the strength of LD increases according to the color order of blue < gray < red. LD, linkage disequilibrium.
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Table XI. Relationship of SNPs identified in the present study to each trait of metabolic syndrome.
Gene SNP Waist circumference (cm) P-value
CCDC6 rs1053266 A/C AA AC CC <0.0001
   81.0±10.6 83.8±10.4 87.0±8.6 
APOA5 rs2075291 G/T GG GT TT 0.0012
   82.0±10.6 83.7±10.3 82.8±10.3 
OR4F6 rs141569282 G/A GG GA  <0.0001
   83.2±10.4 79.1±10.8  
HLA‑DQB2 rs200716952 C/T CC CT  <0.0001
   82.5±10.5 79.5±10.7  
OR52E4 rs11823828 T/G TT TG GG   0.0159
   81.8±10.8 81.8±10.8 83.2±10.3 
 rs17482753 G/T GG GT TT   0.0070
   82.5±10.7 81.3±10.3 83.2±10.9 
Gene SNP Serum triglycerides (mmol/l) P-value
CCDC6 rs1053266 A/C AA AC CC <0.0001
   1.45±1.21 1.79±1.46 2.13±1.33 
APOA5 rs2075291 G/T GG GT TT <0.0001
   1.51±1.15 2.06±1.84 2.71±2.63 
OR4F6 rs141569282 G/A GG GA  <0.0001
   1.71±1.38 1.19±1.00  
HLA‑DQB2 rs200716952 C/T CC CT  <0.0001
   1.62±1.32 1.26±1.11  
OR52E4 rs11823828 T/G TT TG GG   0.0003
   1.52±1.22 1.49±1.15 1.74±1.41 
 rs17482753 G/T GG GT TT <0.0001
   1.65±1.32 1.41±1.22 1.55±1.72 
Gene SNP Serum HDL-cholesterol (mmol/l) P-value
CCDC6 rs1053266 A/C AA AC CC <0.0001
   1.59±0.49 1.39±0.48 1.17±0.35 
APOA5 rs2075291 G/T GG GT TT <0.0001
   1.53±0.50 1.38±0.48 1.28±0.43 
OR4F6 rs141569282 G/A GG GA  <0.0001
   1.44±0.49 1.72±0.42  
HLA‑DQB2 rs200716952 C/T CC CT  <0.0001
   1.49±0.47 1.69±0.47  
OR52E4 rs11823828 T/G TT TG GG   0.0001
   1.54±0.49 1.54±0.51 1.44±0.47 
 rs17482753 G/T GG GT TT <0.0001
   1.48±0.49 1.58±0.53 1.62±0.52 
Gene SNP Systolic blood pressure (mmHg) P-value
CCDC6 rs1053266 A/C AA AC CC <0.0001
   122±22 134±28 145±26 
APOA5 rs2075291 G/T GG GT TT   0.0493
   127±25 130±24 132±30 
OR4F6 rs141569282 G/A GG GA  <0.0001
   131±27 115±16  
HLA‑DQB2 rs200716952 C/T CC CT  <0.0001
   128±26 117±17  
OR52E4 rs11823828 T/G TT TG GG <0.0001
   125±24 126±25 130±25 
 rs17482753 G/T GG GT TT   0.0616
   128±25 126±25 130±23 
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We examined the genes, chromosomal loci, and SNPs identi-
fied in the present study to phenotypes previously reported by 
GWASs available in Genome-Wide Repository of Associations 
Between SNPs and Phenotypes (GRASP) Search database 
(https://grasp.nhlbi.nih.gov/Search.aspx) developed by the 
Information Technology and Applications Center, National 
Center for Biotechnology Information, National Heart, Lung, 
and Blood Institute, National Institute of Health (Bethesda, 
MD, USA).
In the T2DM study, none of the three genes or SNPs was 
shown to be associated with T2DM or diabetes-related traits in 
previous GWASs (Table XIII). In the MetS study, HLA‑DQB2 
was shown to be related to T1DM and plasma total cholesterol; 
rs17482753 at chromosome 8p21.3 to plasma concentrations 
of triglycerides and HDL‑cholesterol; CCDC6 to serum uric 
acid level; and APOA5 to plasma concentrations of triglyc-
erides, HDL-cholesterol, and LDL-cholesterol (Table XIV). 
In the hyperuricemia study, SLC2A9, SLC22A12, and BRAP 
were shown to be related to serum uric acid concentrations; 
rs12229654 at 12q24.1 to plasma HDL‑cholesterol; ACAD10 
to plasma LDL‑cholesterol and T1DM; and HECTD4 to 
plasma HDL-cholesterol and LDL-cholesterol and FPG level 
(Table XV).
Discussion
T2DM, MetS, and hyperuricemia are important public health 
problems because of the high prevalence of these conditions 
as well as risk factors for more serious conditions such as 
cardiovascular disease, cancer, or gout (1,3,4,23,24,33‑35). 
Identification of genetic variants that confer susceptibility to 
T2DM, MetS, and hyperuricemia are thus clinically important 
to prevent these conditions. We have now performed EWASs 
for T2DM, MetS, and hyperuricemia in early-onset subjects 
with these conditions who likely had greater genetic compo-
nents compared with late-onset individuals.
In the T2DM study, rs150552771 of LPGAT1, rs140232911 
of ZNF860, and rs141569282 of OR4F6 were significantly 
associated with early-onset T2DM. None of these genes was 
shown to be associated with T2DM or diabetes-related traits 
in the previous GWASs. Given that rs150552771 of LPGAT1 
was not related to FPG level or blood hemoglobin A1c content, 
LPGAT1 was removed from new susceptibility locus, even 
though this discrepancy may be attributable to the effect of 
medical treatment for T2DM. We have thus newly identified 
ZNF860 and OR4F6 as susceptibility loci for T2DM. A SNP 
rs141569282 of OR4F6 was significantly related to FPG level 
Table XI. Continued.
Gene SNP Diastolic blood pressure (mmHg) P-value
CCDC6 rs1053266 A/C AA AC CC <0.0001
   75±14 79±16 82±16 
APOA5 rs2075291 G/T GG GT TT   0.0055
   76±15 78±14 80±13 
OR4F6 rs141569282 G/A GG GA  <0.0001
   78±15 71±13  
HLA‑DQB2 rs200716952 C/T CC CT    0.0002
   77±15 73±13  
OR52E4 rs11823828 T/G TT TG GG   0.5502
   76±15 76±15 76±14 
 rs17482753 G/T GG GT TT   0.3685
   76±15 76±15 77±14 
Gene SNP Fasting plasma glucose (mmol/l) P-value
CCDC6 rs1053266 A/C AA AC CC <0.0001
   5.90±2.05 6.90±3.33 7.41±3.02 
APOA5 rs2075291 G/T GG GT TT   0.2227
   6.25±2.57 6.46±2.77 6.15±1.77 
OR4F6 rs141569282 G/A GG GA  <0.0001
   6.53±2.87 5.34±0.76  
HLA‑DQB2 rs200716952 C/T CC CT  <0.0001
   6.36±2.67 5.41±1.05  
OR52E4 rs11823828 T/G TT TG GG   0.0001
   6.09±2.32 6.07±2.30 6.57±2.95 
 rs17482753 G/T GG GT TT   0.0048
   6.35±2.63 6.03±2.42 6.55±2.78 
Data are means ± standard deviations and compared among genotypes by one‑way analysis of variance. Based on Bonferroni's correction, 
P‑values of <0.0014 (0.05/36) were considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism.
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and blood hemoglobin A1c content with the minor A allele being 
related to decreases in these parameters, while rs140232911 of 
ZNF860 was related to blood hemoglobin A1c content with the 
minor T allele being related to an increase in this parameter. 
Analyses of these traits as well as logistic regression analysis 
indicate that the A allele of rs141569282 in OR4F6 is protec-
tive against T2DM, whereas the T allele of rs140232911 in 
ZNF860 is a risk factor for this condition.
In the MetS study, six SNPs in five genes and one chro-
mosomal locus were significantly associated with early‑onset 
MetS. Of these genes and locus, HLA‑DQB2 (63), rs17482753 
at 8p21.3 (63), and APOA5 (63) were previously shown to 
be related to lipid profiles; and CCDC6 to serum uric acid 
level (46). OR52E4 or OR4F6 has not been shown to be associ-
ated with MetS or MetS-related traits in the previous GWASs. 
A SNP rs11823828 of OR52E4 was significantly related to 
serum concentrations of triglycerides and HDL-cholesterol, 
systolic BP, and FPG level; and rs141569282 of OR4F6 to all 
traits. We have thus newly identified OR52E4 and OR4F6 as 
susceptibility loci for MetS. The minor G allele of rs11823828 
in OR52E4 was significantly related to increased serum 
triglycerides, decreased serum HDL-cholesterol, increased 
systolic BP, and increased FPG level, whereas the minor 
A allele of rs141569282 in OR4F6 was related to reduced 
waist circumference, decreased serum triglycerides, increased 
serum HDL-cholesterol, decreased systolic and diastolic BP, 
and reduced FPG level. Analyses of these traits and logistic 
regression analysis indicate that the G allele of rs11823828 in 
OR52E4 represents a risk factor for MetS, whereas the A allele 
of rs141569282 in OR4F6 is protective against this condition.
In the hyperuricemia study, 9 SNPs in seven genes 
and one chromosomal locus were significantly associated 
with early-onset hyperuricemia. Of these genes and locus, 
SLC2A9 (46), SLC22A12 (46), and BRAP (46) were previously 
shown to be related to serum uric acid level; and rs12229654 
at 12q24.1 (64), ACAD10 (63), and HECTD4 (63) to lipid 
profiles. HERPUD2 or CCDC63 has not been shown to be 
associated with hyperuricemia, gout, or serum uric acid level 
Table XII. Relationship of SNPs identified in the present study to the serum concentration of uric acid.
Gene SNP Serum uric acid (µmol/l) P‑value
SLC22A12 rs121907892 G/A GG GA AA <0.0001
   333±91 231±82 52±19 
BRAP rs3782886 A/G AA AG GG   0.0002
   332±97 324±91 318±88 
ACAD10 rs11066015 G/A GG GA AA   0.0004
   332±97 324±91 319±88 
HECTD4 rs11066280 T/A TT TA AA   0.0006
   332±96 325±92 318±87 
 rs12229654 T/G TT TG GG   0.0002
   331±96 326±91 312±84 
SLC2A9 rs3775948 G/C GG GC CC <0.0001
   335±94 328±92 312±96 
HERPUD2 rs2305335 T/A TT TA AA <0.0001
   327±93 358±116 407±88 
CCDC63 rs10774610 T/C TT TC CC   0.0067
   330±96 325±91 318±92 
CCDC63 rs10849915 T/C TT TC CC   0.0083
   330±96 325±91 318±92 
Data were means ± standard deviations and compared among genotypes by one‑way analysis of variance. Based on Bonferroni's correction, 
P‑values of <0.0056 (0.05/9) were considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism.
Table XIII. Relationship of genes and SNPs associated with type 2 diabetes mellitus in the present study to previously reported 
diabetes-related phenotypes.
Gene SNP Chromosome Position Previously reported phenotypes
LPGAT1 rs150552771   1 211783358 None
ZNF860 rs140232911   3 31989561 None
OR4F6 rs141569282 15 101806068 None
Data were obtained from Genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (https://grasp.
nhlbi.nih.gov/Search.aspx) with a P-value of <1.0x10-6. SNP, single nucleotide polymorphism.
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in the previous GWASs. A SNP rs2305335 of HERPUD2 
was significantly related to the serum uric acid level, whereas 
two SNPs of CCDC63 were not related to this parameter. 
Therefore CCDC63 was removed from new loci. We have thus 
newly identified HERPUD2 as a susceptibility locus for hyper-
uricemia. The minor A allele of rs2305335 in HERPUD2 was 
significantly related to increased serum uric acid. Examination 
of this trait and logistic regression analysis indicate that the 
A allele of rs2305335 in HERPUD2 represents a risk factor or 
hyperuricemia. Furthermore, OR4F6 was significantly associ-
ated with both T2DM and MetS. We thus newly identified four 
genes (ZNF860, OR4F6, OR52E4, HERPUD2) that confer 
susceptibility to early-onset T2DM, MetS, or hyperuricemia.
We previously showed that four, five, or three SNPs were 
related to T2DM (P<1.44x10-4), MetS (P<0.05), or hyperuri-
cemia (P<0.05) determined by multivariable logistic regression 
Table XIV. Relationship of genes, chromosomal locus, and SNPs associated with metabolic syndrome in the present study to 
previously reported metabolic disease-related phenotypes.
Gene/chr. locus SNP Chr. Position Previously reported phenotypes
HLA‑DQB2 rs200716952   6 32758997 Type 1 diabetes (17554300, 17632545),
    total cholesterol (20686565)
8p21.3 rs17482753   8 19975135 Triglycerides (20686565, 23063622, 19060906, 
    18193043, 21943158, 18179892, 19913121, 17463246), 
    HDL‑cholesterol (20686565, 23063622, 19060906, 
    21943158, 20031538, 20370913, 20339536, 19913121)
CCDC6 rs1053266 10 59792934 Serum urate (23263486)
OR52E4 rs11823828 11 5884973 None
APOA5 rs2075291 11 116790676 Triglycerides (20686565, 23063622, 22629316, 19060906,
    21943158, 19913121, 18193043, 19802338, 23505323,
    23236364, 21386085, 19197348), HDL‑cholesterol 
    (23063622, 22629316, 20686565, 21386085, 19913121, 
    23236364), LDL‑cholesterol (20686565, 19913121), total
    cholesterol (20686565, 23063622, 20339536, 18179892)
OR4F6 rs141569282 15 101806068 None
Data were obtained from Genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (https://grasp.
nhlbi.nih.gov/Search.aspx) with a P-value of <1.0x10-6. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., 
chromosome.
Table XV. Relationship of genes, chromosomal locus, and SNPs associated with hyperuricemia in the present study to previously 
reported metabolic disease-related phenotypes.
Gene/chr. locus SNP Chr. Position Previously reported phenotypes
SLC2A9 rs3775948   4 9993558 Serum urate (23263486)
HERPUD2 rs2305335   7 35638368 None
SLC22A12 rs121907892 11 64593747 Serum urate (20139978, 23263486, 
    21768215, 20884846, 19503597)
CCDC63 rs10849915 12 110895818 None
 rs10774610 12 110902439 None
12q24.1 rs12229654 12 110976657 HDL‑cholesterol (21909109)
BRAP rs3782886 12 111672685 Serum urate (23263486)
ACAD10 rs11066015 12 111730205 LDL‑cholesterol (20686565),
    type 1 diabetes (17554300)
HECTD4 rs11066280 12 112379979 HDL‑cholesterol (21572416, 21909109, 
    22751097), LDL‑cholesterol (21572416, 
    20686565), fasting blood glucose (23575436)
Data were obtained from Genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (https://grasp.
nhlbi.nih.gov/Search.aspx) with a P-value of <1.0x10-6. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., 
chromosome.
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analysis with adjustment for age and sex after the initial 
EWAS screening of allele frequencies in both early-onset 
and late‑onset individuals with these conditions (54‑56). The 
relationship of two of four SNPs [rs138313632 (P=1.11x10-7), 
rs139012426 (P=4.29x10 ‑5)] to T2DM were replicated 
(P<0.05) in the present study. The relationship of two of five 
SNPs [rs1007732 (P=0.0405), rs7350481 (P=3.17x10‑5)] to 
MetS were replicated in the present study. The relationship 
of two of three SNPs [rs115445569 (P=0.0205), rs60854092 
(P=0.0490)] to hyperuricemia were replicated in the present 
study. These results suggest that genetic variants associated 
with T2DM, MetS, or hyperuricemia differ, in part, between 
early-onset and late-onset individuals with these conditions.
There are several limitations to our study: i) Given that the 
results were not replicated, their validation will be necessary 
in independent study populations or in other ethnic groups. 
ii) It is possible that SNPs identified in the present study are 
in LD with other genetic variants in the same gene or in other 
nearby genes that are actually responsible for the develop-
ment of T2DM, MetS, or hyperuricemia. iii) The functional 
relevance of identified SNPs to the pathogenesis of T2DM, 
MetS, or hyperuricemia remains to be elucidated.
In conclusion, we have newly identified four genes (ZNF860, 
OR4F6, OR52E4, HERPUD2) that confer susceptibility to 
early-onset T2DM, MetS, or hyperuricemia. Determination of 
genotypes for the SNPs in these genes may prove informative 
for assessment of the genetic risk for T2DM, MetS, or hyper-
uricemia in Japanese.
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